Clinical and Metabolic Response
therapy-naïve, PBC, breast cancer
DISEASE, PBC, BREAST CANCER
Thirty-two patients had either partial or complete metabolic response after receiving 2 cycles of treatment. Clinically, 22 patients had complete response, 11 had partial response, 2 had stable disease, and 5 had progressive disease. Global Δ-TLG was significantly associated with the clinical response ([Receiver operating characteristic curve analysis of positive metabolic response after 2 cycles of HER2-targeted treatment in breast cancer patients according to [A previously proposed SUVA multivariate model for patient-level prediction of global Δ-TLG using the number of previous treatments, global TLG at baseline, [Number of previous treatments and their effect on response rate measured as Δ-TLG after 2 cycles of HER2-targeted treatment. One-way ANOVA showed significantly different response rates among 3 groups (In contrast to MBC, all PBC patients achieved metabolic response regardless of [Δ-TLG was significantly associated with the number of previous treatments. All therapy-naïve patients achieved a metabolic response regardless of the [